Treating osteoporosis by targeting parathyroid hormone to bone

T. Ponnapakkam, R. Katikaneni, J. Sakon, R. Stratford, R. C. Gensure

Research output: Contribution to journalShort surveypeer-review

45 Scopus citations


Osteoporosis is a major public health problem despite widespread use of bisphosphonate therapy. PTH(1-34) is a more effective treatment; but its use has been limited by side effects (hypercalcemia, tumor risk) and inconvenient dosing (daily injection). Long-acting forms of PTH are also effective but cause severe hypercalcemia, presumably from effects in kidney. We hypothesized that targeted delivery of PTH to bone using a collagen binding domain (PTH-CBD) could reduce hypercalcemia. PTH-CBD is cleared from serum within 12 hours after subcutaneous administration. In ovariectomized rats, monthly administration of PTH-CBD increased spinal BMD by 14.2% with no associated hypercalcemia. Such bone-targeted anabolic agents may ultimately allow the superior efficacy of anabolic therapy to be obtained with the dosing convenience of bisphosphonates.

Original languageEnglish (US)
Pages (from-to)204-208
Number of pages5
JournalDrug Discovery Today
Issue number3
StatePublished - Mar 2014
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Treating osteoporosis by targeting parathyroid hormone to bone'. Together they form a unique fingerprint.

Cite this